Sentivera Launches With a $1.5B Haisco Inflammation Deal as Biotech IPOs Near Escape Velocity (August 26, 2026)

Last updated: August 26, 2026

On August 25, Haisco licensed a preclinical type 2 inflammation drug to Sentivera, a new US company founded by ARCH Venture Partners and Population Health Partners, for $75.89 million upfront in cash and equity plus up to $1.46 billion in milestones, the same day a Leerink banker said the biotech IPO market is approaching escape velocity.

This page covers the Sentivera launch and its full deal terms, the 2026 biotech IPO reopening and Hansa Biopharma’s planned US listing, the still unresolved Amylyx offering close, Eli Lilly’s Foundayo launch in the UK, the Cellares layoffs, the day’s Medicare drug pricing rulings, and the running tally for the week’s scheduled catalysts. All sources are dated and listed at the end.

What is Sentivera and what did it license from Haisco?

Sentivera is a newly formed US biotech founded by Population Health Partners and ARCH Venture Partners. On August 25 it announced an exclusive license to a preclinical Haisco small molecule for type 2 inflammatory diseases, with worldwide rights excluding Greater China, which Haisco retains.

Haisco Pharmaceutical is a Shanghai listed drugmaker. The licensed compound received its China IND approval in August 2026, and the companies say preclinical studies showed strong anti inflammatory activity with a favorable safety profile. Fierce Biotech reports the candidate is aimed at type 2 inflammatory conditions such as asthma and eczema, the territory defined commercially by Dupixent, and that Sentivera was incorporated in Delaware days after Pfizer closed its acquisition of Metsera, the obesity company built by the same two founding firms. Fierce puts that Metsera exit at $10 billion. No individual executives were named in the announcement.

How much is Sentivera paying Haisco?

Per Haisco’s release, Sentivera pays $75.89 million upfront in combined cash and equity consideration, up to $1.46 billion in development, regulatory, and commercial milestones, and tiered royalties running from mid single digit to low double digit rates on net sales. Total potential value exceeds $1.5 billion.

Fierce Biotech, citing deal disclosures, breaks the upfront into roughly $40 million in cash and about $36 million in Sentivera stock, which would hand Haisco a 17.5 percent equity stake in the new company, and reports an $83 million Series A that included a $5 million personal contribution from Haisco chairman Wang Junmin. Those splits are Fierce’s reporting; the $75.89 million combined figure is the company stated number.

How does Sentivera compare to the other new company vehicles of August 2026?

Sentivera is the fourth new company vehicle to price in under two weeks, and the first built privately around a single in licensed asset rather than around a Nasdaq listing. The upfront share of its total deal value, about 5 percent, sits on the same curve as the listing rate card we published on August 24.

The first three vehicles paid their legacy shareholders 5 to 7 percent of the combined company for a clean Nasdaq listing. Sentivera inverts the geometry: the asset seller, not a listing shell, is the one taking equity in the vehicle, and the equity stake Fierce reports is more than double the listing rate card. What Haisco sold was biology; what the reverse merger sellers sold was access. The market is currently paying more for the former.

Why does the Sentivera deal sidestep the fight over Chinese trial data?

Because the asset is preclinical, the license contains no Chinese clinical data for the FDA to evaluate. The August 20 letter from Representatives John Moolenaar and Ben Cline asked the FDA to exclude China generated clinical data unless the trial site was inspected within 12 months. A deal with no human data yet has nothing to exclude.

Every clinical stage Chinese in licensing deal now carries a diligence question we have tracked since August 19: was the human data generated under Order 818’s GMP and safety reporting rules or before them, and would it survive an inspection window if Congress got its way. A preclinical license answers the question by never raising it. The development program that matters to the FDA will be run by Sentivera, presumably in the US, under US rules. If the structure spreads, the politics of Chinese data will show up in deal stage selection before they show up in any statute. Separately on August 25, Representative Nathaniel Moran told Fierce Biotech that China is, in his words, beating us on our ground game in biotech, a reminder that the political temperature around these deals is not falling.

How strong is the biotech IPO market in 2026?

Per BioSpace, 25 biotechs have gone public so far in 2026, five of them in August alone, the most at this point in any year since 2021, with roughly 30 expected by year end. Leerink’s head of equity capital markets, Jack Bannister, described the market as approaching escape velocity.

Bannister’s characterization comes with a quality bar: the companies getting out are mostly later stage with near term clinical milestones, investors are writing $100 million plus orders but staying selective, and properly priced deals trade well. BioSpace cites Kailera Therapeutics’ $625 million IPO and Parabilis Medicines’ $670 million follow up as the year’s records. Bannister also named the two yellow flags that would end the run: preclinical companies rushing to list, and issuers pushing on valuation. Note what the record setter is: Kailera is itself built on obesity assets in licensed from China’s Hengrui. The IPO window and the China licensing pipeline are not separate stories.

The same day, Fierce Pharma and Scrip reported that Hansa Biopharma is laying groundwork for a US listing ahead of the FDA decision on imlifidase (Idefirix), its kidney transplant desensitization therapy, which carries a company disclosed PDUFA date of December 19, 2026. A Stockholm listed company migrating toward Nasdaq before a US approval decision is the same signal from the other direction: the listing venue is the scarce resource.

Has Amylyx closed its $500.2 million offering?

No announcement of the closing had been made as of the evening of August 25. The upsized offering priced August 19 at $35.50 per share with closing expected on or about August 21. We checked the company’s press release index again on August 25; the pricing release remains the most recent.

The underwriters’ 30 day option on 2,113,500 additional shares, roughly $75 million, also remains unexercised as far as public announcements show. To be clear about what this is and is not: offerings close through mechanics that do not always generate a press release, the stock closed August 25 at $37.46, comfortably above the offer price, and nothing suggests distress. But this is the third business day past the stated closing window with no confirmation, in a week whose organizing theme is the scheduled date that produces nothing. A company controlled administrative date is supposed to be the reliable kind. The tally below records it either way.

What is the empty date tally for the week of August 24?

Through August 25, the week’s dated events have produced zero decisions. One dated event produced a new date, Capricor’s PDUFA moving to November 22. The Amylyx closing and the Overton hearing date remain open. The full ratio publishes Friday.

Market note: with no new company news on August 25, Capricor closed at $8.29, up 21.9 percent on the day and up from $6.80 on August 24, exchange close data. The market has now spent two sessions repricing a narrower, dated option upward, which is consistent with the reading we published Tuesday: a known expiry at a lower ceiling beats an open ended silence.

What did Eli Lilly announce about Foundayo in the UK?

Per BioSpace, Lilly launched Foundayo, its oral obesity pill, in the UK on August 25 through private prescription, and is working with NICE on placement in NHS England. The MHRA approved the drug earlier in August. Novo Nordisk’s oral Wegovy received its MHRA clearance in June, a head start of about two months.

No UK price was disclosed for either product in the coverage we reviewed, so we are not stating one. The strategic read is the one our tracked Truist call laid out: ex US markets are more price sensitive, and a synthetic small molecule with no peptide supply chain should be able to chase price in a way an oral peptide cannot. The UK is the first head to head test of that thesis in a major market. For scale, in Q2 the oral duel stood at DKK 3,141 million for oral Wegovy against $98 million for Foundayo’s first quarter, both company reported. Watch the NICE outcome; a public reimbursement listing would be the first hard price signal.

Why is Cellares cutting about 100 jobs?

BioPharma Dive reports that Cellares, the cell therapy manufacturing specialist, will lay off about 100 employees after losing a large pharma customer, which it did not name. Fierce Pharma quotes the CEO describing a resizing of the company. We are not speculating on the customer’s identity.

The relevance to a thesis we run: infrastructure over pipeline works because infrastructure captures value with less binary risk than drug development. Cellares is the caveat. A capacity business concentrated in one large customer carries its own binary, it is just a commercial one rather than a clinical one. The radiopharma buildout, the Roche Hillsboro plant, and the CDMO recovery forecasts all price infrastructure as the safe leg; customer concentration is where that safety leaks.

What else moved in biotech and pharma on August 25, 2026?

Courts closed out two more IRA challenges, Moderna extended its melanoma repricing, and REGENXBIO recovered part of Monday’s loss. The short items, each attributed:

Medicare negotiation litigation. Per Fierce Pharma, a federal appeals court on August 24 rejected Merck’s constitutional challenge to the Medicare drug price negotiation program, and a Maryland federal court dismissed AstraZeneca’s suit days earlier. The pattern matches the map we drew from the Teva ruling on August 20: broad constitutional attacks on the program keep failing, while Teva’s narrow, administrative challenge to the bona fide marketing standard is the one an appeals court just revived.

Moderna follow through. MRNA closed August 25 at $158.83, up from $138.89 the prior session, exchange close data, with press coverage citing analyst target raises and short covering. Still true: no effect sizes and no congress placement have been announced by Merck and Moderna for INTerpath-001 as of the evening of August 25.

REGENXBIO. RGNX closed at $8.91, recovering part of Monday’s 24.9 percent drop. The company filed an 8-K on the RGX-121 clinical hold; the FDA’s full hold letter is still pending.

Bausch + Lomb is advancing a dry eye disease candidate into Phase 3 despite a mid stage miss, per BioSpace. Spruce Biosciences plans a Q4 filing for an ultra rare disease program after productive FDA discussions, per Fierce Biotech. Curium made its case on radiopharmaceutical supply resiliency ahead of its PSMA therapy showdown with Novartis’ Pluvicto, per BioSpace. And Massachusetts biopharma employment fell 3.1 percent in 2025 with R&D roles down 3.9 percent, per a MassBio report covered by BioSpace.

Frequently asked questions

What is Sentivera?

Sentivera is a private US biotech incorporated in Delaware and founded by Population Health Partners and ARCH Venture Partners, the firms behind Metsera. It launched publicly on August 25, 2026 with an exclusive worldwide license, excluding Greater China, to a preclinical Haisco drug for type 2 inflammatory diseases.

How much is the Sentivera and Haisco deal worth?

Total potential value exceeds $1.5 billion: $75.89 million upfront in combined cash and equity, up to $1.46 billion in development, regulatory, and commercial milestones, plus tiered royalties from mid single digit to low double digit rates, per Haisco’s August 25 release.

What disease will the Sentivera drug treat?

The licensed small molecule targets type 2 inflammatory diseases, the immunology territory that includes asthma and atopic dermatitis and is dominated commercially by Dupixent. The compound is preclinical; China’s regulator cleared it for first clinical trials in August 2026.

Who gets equity in Sentivera under the deal?

Fierce Biotech reports Haisco receives about $36 million of its upfront in Sentivera stock, a roughly 17.5 percent stake, and that Haisco’s chairman personally invested $5 million in the $83 million Series A. The combined $75.89 million upfront figure is the company stated number.

Does the Sentivera deal include Chinese clinical trial data?

No. The asset is preclinical, so no human data changes hands. That places the deal outside the scope of the congressional letter asking the FDA to restrict China generated clinical data, because the clinical program will be run by Sentivera going forward.

How many biotech IPOs have priced in 2026?

Twenty five biotech IPOs have priced year to date as of August 25, five of them in August, the strongest count at this point since 2021, with about 30 expected by year end, per BioSpace citing Leerink Partners.

What are the biggest biotech IPOs of 2026?

Per BioSpace, Kailera Therapeutics raised $625 million in the year’s record IPO, and Parabilis Medicines then raised $670 million. Both are later stage companies, consistent with bankers’ description of a selective window favoring de risked assets.

When is Hansa Biopharma’s imlifidase FDA decision?

Hansa has disclosed a PDUFA action date of December 19, 2026 for imlifidase, marketed in Europe as Idefirix, for desensitization in kidney transplant. Fierce Pharma and Scrip report the Stockholm listed company is preparing a US listing ahead of the decision.

Has Amylyx closed its $500.2 million offering?

Not as of the evening of August 25, 2026. The offering priced August 19 at $35.50 with closing expected on or about August 21. No closing or underwriter option announcement had appeared in the company’s press release index when we checked on August 25.

Is Foundayo available in the United Kingdom?

Yes, as of August 25, 2026, through private prescription. The MHRA approved Foundayo earlier in August for obesity and for type 2 diabetes, and Lilly is in discussions with NICE about NHS England reimbursement. No UK price has been disclosed in the coverage we reviewed.

Why did Cellares lay off employees?

Cellares is cutting about 100 positions after losing a large, unnamed pharma customer, per BioPharma Dive. The company builds automated cell therapy manufacturing capacity, and its CEO described the move to Fierce Pharma as resizing the company to current demand.

What happened in the Medicare drug pricing lawsuits this week?

Per Fierce Pharma, an appeals court rejected Merck’s constitutional challenge to Medicare price negotiation on August 24, and a Maryland federal court dismissed AstraZeneca’s case days earlier. Teva’s separate challenge to the bona fide marketing standard, revived on August 18, is the one still moving.

When is Capricor’s new PDUFA date?

November 22, 2026. The FDA classified Capricor’s BLA amendment for deramiocel in Duchenne muscular dystrophy as a major amendment on August 24 and extended the review three months, with the company now asking for an indication focused on upper limb function.

What is the empty date tally?

It is our running count, set August 24, of how many of the week’s scheduled catalyst dates produced actual decisions. Through August 25 the score is zero decisions, one new date issued, and two items, the Amylyx closing and the Overton hearing, still open. The final ratio publishes Friday, August 28.

Sources

Primary sources: Haisco Pharmaceutical license agreement announcement, PR Newswire, August 25, 2026. Amylyx Pharmaceuticals offering pricing release, Business Wire, August 19, 2026. Capricor Therapeutics PDUFA extension release, August 24, 2026. REGENXBIO regulatory update on RGX-121 and associated 8-K, August 24, 2026. Novo Nordisk H1 2026 interim report (oral Wegovy Q2 sales). Eli Lilly Q2 2026 results release (Foundayo Q2 sales). Hansa Biopharma imlifidase PDUFA disclosure.

Trade press and market coverage, August 24 to 25, 2026: Fierce Biotech (Sentivera launch and deal split; Spruce; Moran remarks), BioSpace (biotech IPO market; Foundayo UK launch; Curium; Massachusetts employment; Cellares layoff tracker), BioPharma Dive (Cellares layoffs), Fierce Pharma (Cellares resizing; Hansa US listing; Medicare litigation rulings), Scrip (Hansa listing).

Market data: exchange closing prices for August 25, 2026 via consolidated market data (AMLX $37.46, CAPR $8.29, RGNX $8.91, MRNA $158.83).

Related coverage

For the reverse merger listing rate card and the empty date framework, read our August 24 analysis of Capricor’s silent PDUFA date and the listing rate card. For the Capricor extension, the Roche and Hanmi deal, and the RGX-121 hold, read yesterday’s briefing on the November 22 PDUFA date and the muscle preservation bet. For the framework sorting August’s deal structures, see the binary ledger reference table from August 21.